WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 20'3501 Infant (under 12 months) mortality rate: 52
GDP / capita (US$): 46'9461 Child (under 5 years) mortality rate: 62

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 1'425  1'372  1'336  1'315  1'300  665  496  360 
Births 22  21  21  21  21  15  14  12 
Surviving infants 22  21  21  21  20  15  14  11 
Pop. less than 5 years 107  106  103  101  98  74  66  50 
Pop. less than 15 years 289  286  276  270  265  200  162  124 
Female 15-49 years 323  315  311  308  304  162  113  75 

Number of reported cases

(Click for retrospective incidence data for Bahrain)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  46  59  1'861 
Mumps
ChartChart
  24  36  21  59  29  167 
Pertussis
ChartChart
  106 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Bahrain)
Vaccine year result method % card seen                                                
BCG          93  99*  99*  99*  87  63 
DTP1 1994  99     82  99  98  98  99  99*  98 
DTP3 1994  90     82  99*  98  98  99  99  97  94  92 
DTP4          99*  98  99* 
IPV1          99  98  98  99  99* 
HepB_BD          99*  99  99*  99  99* 
HepB3 1994  88     82  99*  98  98  99  99  97 
Hib3          99*  98  98  99  99  97 
JapEnc         
MCV1          99*  99*  99  99*  99*  98  87  63 
MCV2          99*  99*  99*  99*  99*  92 
MenA         
PCV1          99*  99  99  99*  99* 
PCV2          99*  98  99  99*  99 
PCV3          99*  98  98  99*  99* 
Pol3 1994  90     82  99*  98  98  99  99  97  94  92 
Rota1          98  97  98  98  99 
RotaC          98  97  97  97  96 
RCV1          99*  99*  99  99*  99* 
TT2plus          39  41  30  38  36  71  41 
PAB          99  98  98  98  95  84 
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Bahrain)
DTP1
ChartChart
  99  98  98  99  99  98  97  89 
DTP3
ChartChart
  99  98  98  99  99  97  94  72 
HepB3
ChartChart
  99  98  98  99  99  97 
HepB_BD
ChartChart
  99  67 
Hib3
ChartChart
  99  98  98  99  99  97 
IPV1
  99  98 
MCV1
ChartChart
  99  99  99  99  99  98  87  45 
MCV2
ChartChart
  99  99  99  99  99  92 
PCV3
ChartChart
  99  98  98  99  99 
Pol3
ChartChart
  99  98  98  99  99  97  94  72 
RCV1
ChartChart
  99  99  99  99  99  98  87  45 
RotaC
ChartChart
  98  97  97  97  96 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; No infants born to parents originally from TB endemic area
DT 2, 4, 6, 18 months; 5 years; Yes Children with contraindications or allergic to Pertussis componant of the vaccine
DTaP 5 years; Yes Preschool vaccination at age of 5 yrs and was replaced by DTaPIPV from October 2016
DTaPHibHepIPV 2, 4 months; Yes Routine childhood vaccination given at age of 2 and 4 months
DTaPIPV 5 years; Yes Routine childhood vaccination given 5 years since October 2016 replacing DTaP
DTwPHib 18 months; Yes Routine childhood vaccination given at 18 months, this is replaced by pentavalent if not available.
DTwPHibHepB 6, 18 months; Yes Routine childhood vaccination given at age of 6 months. Also at age of 18 months if tetravalent vaccine (DTaPHib)is not available.
HepA 15 months; 2 years; Yes Routine childhood vaccination given at the age of 15 months and 2 years. Catch-up campaign for school students at age of 12 & 13 yrs.
HepA_Adult x2 doses; Yes High risk groups ,certain occupations at risk including HCW, college students and travellers.
HepB_Adult x3 doses; Yes High risk groups ,certain occupations at risk including HCW, college students and others.
HepB_Pediatric birth; Yes Routine universal hepatitis B birth dose. Other doses received as part of combained vaccine
HIB 5 years; Yes Given as single dose for >5 years children with sickle cell disease, anatomical and/or surgical asplenia, post bone marrow transplant and certain cancer after finishing treatment.
HPV No available only in the private sector
Influenza Children; elderly; risk groups Yes and healthcare workers, obese, residents of nursing homes& other long term facilities , household of high risks of flu complications, offered to any one requesting the vaccine
IPV 2, 4, 6, 18 months; 5 years; Yes For immunocompromized and their household members
MenACWY-135 conj 2 years; Yes Routine childhood vaccination. Also given to high risk groups and to travelers to Holly places, meningitis belt countries and countries reporting outbreak.
MMR 12, 18 months; Yes Routine childhood vaccination, given at 1 year and 18 months. Also, it is given for non-immune women at reproductive age group discovered during premarital counselling and postnatally for non-immune women discovered during antenatal screening.
OPV 4, 6, 18 months; 5 years; Yes Routine childhood vaccination, traveller to polio endemic countries
Pneumo_conj 2, 4, 6, 15 months; Yes Routine childhood vaccination. As a single dose for adults at >=50 years and for high risk groups at age 5-50 years.
Pneumo_ps >=65 years; Yes Routinely for those at age of 65 yrs and above and High Risk Groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose after 5 years.
Rotavirus 2, 4 months; Yes
Td >7 years; Yes Pregnant women, Post trauma, certain occupations at risk &Haj pilgrims, others at risk of exposure
Tdap 13 years; Yes School students Vaccination, elderly and other at risk.
Typhoid Yes Travellers, certain occupations at risk
Varicella 1, 3 years; Yes Routine childhood vaccine given at one year and three years of age. Also, the vaccine is given to high risk groups including HCW at direct patient care, household of oncology patient and others
YF Yes Travellers to YF endemic countries

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2015-2020  2015-2020  2012-2017  2013-2015  2012-2015     
Nº of districts with microplans that include activities to raise immunization coverage number    

System performance

Total Nº districts in country number
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100  100  100  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   100  100  100       

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.